- Home
- JBLU vs PTGX Comparison
JBLU vs PTGX Comparison
Compare JBLU & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBLU
- PTGX
- Stock Information
- Founded
- JBLU 1998
- PTGX 2006
- Country
- JBLU United States
- PTGX United States
- Employees
- JBLU N/A
- PTGX N/A
- Industry
- JBLU Air Freight/Delivery Services
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- JBLU Consumer Discretionary
- PTGX Health Care
- Exchange
- JBLU Nasdaq
- PTGX Nasdaq
- Market Cap
- JBLU 2.0B
- PTGX 2.8B
- IPO Year
- JBLU N/A
- PTGX 2016
- Fundamental
- Price
- JBLU $5.67
- PTGX $47.91
- Analyst Decision
- JBLU Hold
- PTGX Strong Buy
- Analyst Count
- JBLU 10
- PTGX 7
- Target Price
- JBLU $6.31
- PTGX $52.83
- AVG Volume (30 Days)
- JBLU 17.0M
- PTGX 450.1K
- Earning Date
- JBLU 10-29-2024
- PTGX 11-08-2024
- Dividend Yield
- JBLU N/A
- PTGX N/A
- EPS Growth
- JBLU N/A
- PTGX N/A
- EPS
- JBLU N/A
- PTGX 2.75
- Revenue
- JBLU $9,327,000,000.00
- PTGX $319,120,000.00
- Revenue This Year
- JBLU N/A
- PTGX $400.33
- Revenue Next Year
- JBLU $4.68
- PTGX N/A
- P/E Ratio
- JBLU N/A
- PTGX $17.54
- Revenue Growth
- JBLU N/A
- PTGX 125.73
- 52 Week Low
- JBLU $3.42
- PTGX $13.76
- 52 Week High
- JBLU $8.07
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- JBLU 38.78
- PTGX 60.40
- Support Level
- JBLU $6.86
- PTGX $45.33
- Resistance Level
- JBLU $7.49
- PTGX $48.89
- Average True Range (ATR)
- JBLU 0.37
- PTGX 1.28
- MACD
- JBLU -0.18
- PTGX 0.11
- Stochastic Oscillator
- JBLU 0.46
- PTGX 77.11
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The operating segments of company are Domestic & Canada, Caribbean & Latin America and Atlantic. Majority of revenue is generated from Domestic & Canada segment.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.